Peptonics enters into VagiVital® distributor agreement with Revisage in Poland

Report this content

Peptonic Medical (publ) (“Peptonic” or “Bolaget”) today announced it has signed a distributor agreement with Revisage concerning sales and distribution of VagiVital® AktivGel in Poland. Revisage is granted the exclusive rights to market and sell VagiVital® AktivGel to medical and aesthetic clinics in Poland.

– We are very pleased to have entered into this agreement with Revisage. It gives us an excellent opportunity to assess the reception of VagiVital® in a channel where treatments of vaginal medical conditions are growing fast. We still view the pharmacy channel as the biggest potential for the VagiVital® range and we aim to get there in Poland as well. However, we believe that this is an exciting new way of opening a new market and we are looking forward to a mutually beneficial cooperation with Revisage, says Erik Sundquist, CEO of Peptonic Medical.

– We are very much looking forward to launching VagiVital® in Poland. Amongst our clinic customers we see a quick growth of the number of treatments of medical vaginal conditions. With its high level of clinical evidence, excellent function and a gel specifically developed for the vaginal environment we see VagiVital® AktivGel as a great addition to our portfolio, says Mariusz Dziubiński, Founder & CEO of Revisage.

Erik Sundquist, CEO

Telefon: + 46 722 49 90 43


This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17th May, 2021.

About VagiVital® AktivGel

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital®was launched in Sweden as a non-prescription self-care product in July 2018 (see 

About Peptonic Medical AB

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research, develops and sells products conducts in the field of women’s health. Our vision is to offer safe and effective treatments for women-specific diseases, medical conditions and well being. Peptonic Medical launched VagiVital® AktivGel in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness. The company’s development program also includes Vagitocin® – a product that contains oxytocin for the treatment of vaginal atrophy. The development of Vagitocin® has been put on hold pending new information regarding the mechanism of action of oxytocin in this indication. The company was founded in 2009 and the share has been traded since 2014 on Spotlight (, short code: PMED) in Stockholm.

Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical. The company’s business concept is to lead a menstrual revolution in a positive spirit. By focusing on sustainable development, environmental issues and the promotion of sexual health, the company has developed to take the lead for the menopausal companies. Lunette® menstrual cups are an alternative to disposable menstrual protection and last for several years. Lunette® menstrual cups are designed, manufactured and packaged in Finland. For more information about Lunette®, visit

About Revisage

Revisage is a privately own medical device company who imports, markets and sells products to primarily dermatological and aesthetic clinics in Poland. The head office is in Warzaw and the company was founded 2012. Revisage has noticed a rapid growth in the demand for medical treatment for vaginal health conditions amongst their customers. The company will meet this increasing demand by building a portfolio for this purpose.